These five FERNE clinical summaries provide a comprehensive update on the evaluation and management of emergency department patients with mild traumatic brain injury (mTBI), emphasizing the integration of clinical assessment, neuroimaging, and emerging diagnostic strategies.
They examine the clinical role of the blood biomarkers GFAP and UCH-L1, including FDA-cleared applications, diagnostic performance, appropriate patient selection, limitations, confounding factors, and their potential to safely reduce unnecessary head CT imaging.
The summaries review recent evidence, including the Puravet systematic review/meta-analysis and ALERT-TBI data, and specifically examine the uncommon but important patients with negative biomarkers despite CT-positive traumatic findings. They also extend beyond acute diagnosis to address concussion diagnosis, persistent symptoms, recovery, early graded activity, symptom-directed treatment, and appropriate discharge and follow-up care.
Together, the five summaries provide a clinically focused framework for understanding where current evidence supports mTBI testing and management, where important limitations remain, and how this evidence can be incorporated into everyday emergency medicine practice.
Mild Traumatic Brain Injury Patients in the Emergency and Primary Care Settings Documents
Why Read These FERNE Documents as a Clinical Update?
As a clinical update, these summaries bring together evolving evidence about mTBI diagnosis, CT utilization, brain biomarkers, concussion management, and recovery into information that can be directly applied to ED patient care. They help clinicians reconsider established practices and incorporate newer approaches—including selective biomarker testing, appropriate neuroimaging, early activity, symptom-based management, and structured follow-up—into contemporary mTBI care.
Why Use These FERNE Documents as a Journal Club?
As a journal club, these summaries provide an opportunity to examine the primary studies, systematic reviews, clinical guidelines, and regulatory evidence underlying current mTBI practice rather than simply accepting the resulting recommendations. Comparing studies such as ALERT-TBI with the more recent Puravet systematic review/meta-analysis also demonstrates how differences in study design, patient populations, diagnostic thresholds, and pooled versus prospective data can influence the interpretation and clinical application of the evidence.